- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05470244
TENS in Post-operative Total Knee Arthroplasty Recovery and Intra-venous Analgesics Requirement
April 5, 2023 updated by: Ayesha Jamil, University of Lahore
Effects of Transcutaneous Electrical Nerve Stimulation in Post-operative Total Knee Arthroplasty Recovery and Intra-venous Analgesics Requirement
Total knee arthroplasty (TKA) is among the major advancements for the treatment of knee pain and improvement of physical function when conservative management fails to comply with.
The success of this arthoplasty results in more functional mobility and better quality of life.
However, management of pain after TKA in post-operative period is a big challenge to deal.
Study Overview
Status
Completed
Conditions
Detailed Description
Transcutaneous electrical nerve stimulation is a cost effective, non-invasive electrotherapeutic modality used in alleviating pain in both acute and chronic conditions affecting neuromusculoskeletal system of the body.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Punjab
-
Lahore, Punjab, Pakistan, 54000
- The University of Lahore
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
31 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Both male and female
- Aged between 31-70 years
- Total Knee Arthoplasty, who had been diagnosed with knee osteoarthritis, inflammatory arthritis, trauma, fracture result in total knee arthoplasty.
Exclusion Criteria:
- Any allergic condition of skin
- Chronic consumption of opioids
- History of dysplasia or malignancy to knee joint
- Any major bone operation of lower limb
- BMI higher than 35 kg m-2
- History of mental disorder
- Neurological illness e.g. Alzheimer which might interfere with assessment process.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Therapeutic Exercise Group
This group will receive Routine Physical therapy protocol along with prescribed intra-venous regimen.
|
ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
|
|
Experimental: TENS Plus Therapeutic Exercise Group
This group will receive high frequency Transcutaneous Electrical Nerve Stimulation with routine physical therapy and prescribed intra-venous regimen.
|
High frequency stimulations via Transcutaneous Electrical Nerve Simulator will be applied.
ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Intensity
Time Frame: Pain intensity will be measured at baseline,and change in pain intensity will be measured from baseline to 24 hour, 48 hour and 72 hours.
|
Pain intensity will be measured using Visual Analogue Scale
|
Pain intensity will be measured at baseline,and change in pain intensity will be measured from baseline to 24 hour, 48 hour and 72 hours.
|
|
Rang of Motion
Time Frame: Knee Range of Motion will be measured at baseline, and Change in Knee Range of Motion will be measured from baseline to 24 hour, 48 hour and 72 hours
|
Knee Rang of Motion will be measured using Universal Goniometer
|
Knee Range of Motion will be measured at baseline, and Change in Knee Range of Motion will be measured from baseline to 24 hour, 48 hour and 72 hours
|
|
Intra-venous analgesic requirement
Time Frame: Analgesics requirement will be observed at first post-operative day, at second post-operative day, at third post-operative day
|
Dose and frequency of intravenous analgesic requirement will be observed through Patient's file
|
Analgesics requirement will be observed at first post-operative day, at second post-operative day, at third post-operative day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of Hospital Stay
Time Frame: It will be measured from the time of randomization till the time of discharge from hospital upto ten days
|
Length of Hospital Stay of patient
|
It will be measured from the time of randomization till the time of discharge from hospital upto ten days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Prof. Dr. Ashfaq Ahmed, PhD, The University of Lahore
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 13, 2022
Primary Completion (Actual)
December 15, 2022
Study Completion (Actual)
December 15, 2022
Study Registration Dates
First Submitted
July 12, 2022
First Submitted That Met QC Criteria
July 20, 2022
First Posted (Actual)
July 22, 2022
Study Record Updates
Last Update Posted (Actual)
April 7, 2023
Last Update Submitted That Met QC Criteria
April 5, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TKR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
it will be shared immediately after publication
IPD Sharing Time Frame
Beginning 9 months and ending on 36th month
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.